Growth HormoneIn Clinical Trials
CJC-1295
CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.
Clinical Trials100 mcg daily (no DAC)
Peptide Database
Browse Research Peptides
Comprehensive profiles for 105+ peptides — dosing protocols, mechanisms of action, clinical research, and safety data.
105
Peptides
9
Categories
9 peptides match your filters
Growth HormoneNot FDA Approved
CJC-1295 DAC
Modified GRF 1-29 DAC
CJC-1295 variant containing a reactive linker that binds to albumin after injection, extending half-life from minutes to 6-8 days for sustained GHRH stimulation.
Clinical Trials1-2 mg weekly
Growth HormoneNot FDA Approved
GHRP-2
Growth Hormone Releasing Peptide 2
A synthetic hexapeptide that acts on ghrelin receptors to stimulate GH release from the pituitary. Has the strongest GH-releasing effect among GHRPs.
Clinical Trials100-300 mcg per injection
Growth HormonePreclinical
GHRP-6
Growth Hormone Releasing Peptide 6
One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite.
Clinical Trials100-300 mcg, 2-3x daily
Growth HormoneIn Clinical Trials
Hexarelin
Examorelin
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing effect among GHRPs. Also has notable cardioprotective properties independent of GH release.
Clinical Trials100-200 mcg per injection
Growth HormoneIn Clinical Trials
Ipamorelin
IPAM
A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.
Clinical Trials200-300 mcg, 2-3x daily
Growth HormoneIn Clinical Trials
MK-677
Ibutamoren
An orally active growth hormone secretagogue that mimics ghrelin. Provides 24-hour GH elevation due to long half-life.
Clinical Trials10-25 mg daily
Growth HormoneNot FDA Approved
Sermorelin
Geref
A truncated analog of natural GHRH containing the first 29 amino acids, used off-label for hormone optimization.
Animal Studies200-500 mcg before bed
Growth HormoneFDA Approved
Tesamorelin
Egrifta
An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
FDA Approved2 mg daily (F8: 1.28 mg daily)